87 related articles for article (PubMed ID: 20944133)
1. Differential expression of mTOR signalling components in drug resistance in ovarian cancer.
Foster H; Coley HM; Goumenou A; Pados G; Harvey A; Karteris E
Anticancer Res; 2010 Sep; 30(9):3529-34. PubMed ID: 20944133
[TBL] [Abstract][Full Text] [Related]
2. Expression of mTOR and downstream signalling components in the JEG-3 and BeWo human placental choriocarcinoma cell lines.
Mparmpakas D; Zachariades E; Foster H; Kara A; Harvey A; Goumenou A; Karteris E
Int J Mol Med; 2010 Jan; 25(1):65-9. PubMed ID: 19956903
[TBL] [Abstract][Full Text] [Related]
3. Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation.
Kobayashi T; Shimizu Y; Terada N; Yamasaki T; Nakamura E; Toda Y; Nishiyama H; Kamoto T; Ogawa O; Inoue T
Prostate; 2010 Jun; 70(8):866-74. PubMed ID: 20127734
[TBL] [Abstract][Full Text] [Related]
4. MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma.
Grzmil M; Morin P; Lino MM; Merlo A; Frank S; Wang Y; Moncayo G; Hemmings BA
Cancer Res; 2011 Mar; 71(6):2392-402. PubMed ID: 21406405
[TBL] [Abstract][Full Text] [Related]
5. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
Duan Z; Foster R; Bell DA; Mahoney J; Wolak K; Vaidya A; Hampel C; Lee H; Seiden MV
Clin Cancer Res; 2006 Sep; 12(17):5055-63. PubMed ID: 16951221
[TBL] [Abstract][Full Text] [Related]
6. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
[TBL] [Abstract][Full Text] [Related]
7. Involvement of mTOR and survivin inhibition in tamoxifen-induced apoptosis in human hepatoblastoma cell line HepG2.
Guo R; Wang T; Shen H; Ge HM; Sun J; Huang ZH; Shu YQ
Biomed Pharmacother; 2010 Apr; 64(4):249-53. PubMed ID: 19931998
[TBL] [Abstract][Full Text] [Related]
8. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.
Fornari F; Milazzo M; Chieco P; Negrini M; Calin GA; Grazi GL; Pollutri D; Croce CM; Bolondi L; Gramantieri L
Cancer Res; 2010 Jun; 70(12):5184-93. PubMed ID: 20501828
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.
Faried LS; Faried A; Kanuma T; Nakazato T; Tamura T; Kuwano H; Minegishi T
Eur J Cancer; 2006 May; 42(7):934-47. PubMed ID: 16540312
[TBL] [Abstract][Full Text] [Related]
10. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
11. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.
Lamendola DE; Duan Z; Yusuf RZ; Seiden MV
Cancer Res; 2003 May; 63(9):2200-5. PubMed ID: 12727840
[TBL] [Abstract][Full Text] [Related]
12. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics.
Dai B; Kong YY; Ye DW; Ma CG; Zhou X; Yao XD
BJU Int; 2009 Oct; 104(7):1009-16. PubMed ID: 19389013
[TBL] [Abstract][Full Text] [Related]
13. The rationale for mTOR inhibition in epithelial ovarian cancer.
Trinh XB; van Dam PA; Dirix LY; Vermeulen PB; Tjalma WA
Expert Opin Investig Drugs; 2009 Dec; 18(12):1885-91. PubMed ID: 19888868
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
15. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.
Wang ZG; Fukazawa T; Nishikawa T; Watanabe N; Sakurama K; Motoki T; Hatakeyama S; Omori O; Ohara T; Tanabe S; Fujiwara Y; Takaoka M; Shirakawa Y; Yamatsuji T; Tanaka N; Naomoto Y
Oncol Rep; 2010 Apr; 23(4):1167-72. PubMed ID: 20204306
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma.
Miyazawa M; Yasuda M; Fujita M; Kajiwara H; Hirabayashi K; Takekoshi S; Hirasawa T; Murakami M; Ogane N; Kiguchi K; Ishiwata I; Mikami M; Osamura RY
Pathol Int; 2009 Jan; 59(1):19-27. PubMed ID: 19121088
[TBL] [Abstract][Full Text] [Related]
17. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I
Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
19. S100P contributes to chemosensitivity of human ovarian cancer cell line OVCAR3.
He Z; Gao J; Wang Q; Liu M; Li Y; Li X; Tang H; Zheng J
Oncol Rep; 2008 Aug; 20(2):325-32. PubMed ID: 18636193
[TBL] [Abstract][Full Text] [Related]
20. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.
Hou G; Xue L; Lu Z; Fan T; Tian F; Xue Y
Cancer Lett; 2007 Aug; 253(2):236-48. PubMed ID: 17360108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
